Comparing 50 mg and 100 mg daily aspirin for older adults with cardiovascular disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, prospective cohort extension of the LAPIS cohort that compares long-term outcomes for Chinese patients aged 60+ taking 50 mg versus 100 mg of aspirin daily for secondary prevention of atherosclerotic cardiovascular disease. The study follows participants for an additional two years (up to about six years total) and collects outcomes by telephone, clinic visits, and review of electronic medical records. The primary effectiveness outcome is the first occurrence of major adverse cardiovascular events (MACE) and safety outcomes focus on bleeding events. The cohort builds on prior enrollment of thousands of participants receiving long-term aspirin for secondary prevention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 60 years.
2. Diagnosis of established atherosclerotic cardiovascular disease (ASCVD), including acute coronary syndrome, stable coronary artery disease, post-revascularization (percutaneous coronary intervention or coronary artery bypass grafting), ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, or peripheral artery disease.
3. Long-term use of aspirin (≥1 year) for secondary prevention of ASCVD.
4. Available laboratory tests (within the past 3 months): complete blood count, urinalysis, routine stool examination and occult blood test, liver and kidney function, electrolytes, glucose, lipids, uric acid, coagulation function, etc.
5. Willing to provide written informed consent.

Exclusion Criteria:

1. Hypersensitivity to aspirin or other salicylates, or any other component of the drug product; history of asthma induced by salicylates or nonsteroidal anti-inflammatory drugs (NSAIDs), or any other condition that, in the clinical judgment, makes the patient unsuitable for study participation.
2. Life expectancy ≤ 2 years due to non-cardiovascular causes.
3. Poor compliance (unable to adhere to prescribed medication or follow scheduled follow-up visits as judged by the investigator).

Where it's running

• Peking University First Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Meilin Liu, MD
• Email: liumeilin@hotmail.com
• Phone: +86-010-83572022

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Determining the best LDL cholesterol levels for small vessel occlusion stroke prevention

  This study is testing the best cholesterol levels and treatments for people who have had small vessel occlusion strokes to see how they can prevent more strokes.

  Recruiting at 43 sites Seoul National University Hospital · Ansan and 45 other locations · NCT06649240

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Understanding why some people see bigger LDL drops after starting ezetimibe

  This study tests what factors predict how much a person’s LDL cholesterol drops after starting ezetimibe, to help tailor cholesterol treatment.

  Recruiting Phase 4 Universidade do Porto · Porto · NCT07839741

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.